The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma Article

ESI Most Cited Paper

cited authors

  • McGregor, B. A.; Sonpavde, G. P.; Kwak, L.; Regan, M. M.; Gao, X.; Hvidsten, H.; Mantia, C. M.; Wei, X. X.; Berchuck, J. E.; Berg, S. A.; Ravi, P. K.; Michaelson, M. D.; Choueiri, T. K.; Bellmunt, J.

authors

Publication Date

  • January 12, 2024

webpage

published in

category

keywords

  • antibody -drug conjugate
  • enfortumab vedotin
  • sacituzumab govitecan
  • urothelial carcinoma

start page

  • 91

end page

  • 97

volume

  • 35

issue

  • 1